These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28634163)

  • 1. Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.
    Berman ML; Hatsukami DK
    Tob Control; 2018 May; 27(3):352-354. PubMed ID: 28634163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grass roots approach to control levels of carcinogenic nitrosamines, NNN and NNK in smokeless tobacco products.
    Gupta AK; Tulsyan S; Bharadwaj M; Mehrotra R
    Food Chem Toxicol; 2019 Feb; 124():359-366. PubMed ID: 30543893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.
    Berman ML; Bickel WK; Harris AC; LeSage MG; O'Connor RJ; Stepanov I; Shields PG; Hatsukami DK
    Nicotine Tob Res; 2018 Sep; 20(11):1292-1300. PubMed ID: 29059363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications and challenges for implementation of the FDA's final deeming rule for waterpipe tobacco.
    Sutfin EL; Soule EK; McKelvey K; Jenson D
    Tob Control; 2018 May; 27(3):347-351. PubMed ID: 28667092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Survey of N'-Nitrosonornicotine (NNN) and Total Water Content in Select Smokeless Tobacco Products Purchased in the United States in 2015.
    Ammann JR; Lovejoy KS; Walters MJ; Holman MR
    J Agric Food Chem; 2016 Jun; 64(21):4400-6. PubMed ID: 27192054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence supporting product standards for carcinogens in smokeless tobacco products.
    Hatsukami DK; Stepanov I; Severson H; Jensen JA; Lindgren BR; Horn K; Khariwala SS; Martin J; Carmella SG; Murphy SE; Hecht SS
    Cancer Prev Res (Phila); 2015 Jan; 8(1):20-6. PubMed ID: 25524878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
    Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J
    Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Case for Requiring Graphic Warning Labels on Smokeless Tobacco Product Packages.
    Pakhale S; Samet J; Folan P; Leone F; White A;
    Ann Am Thorac Soc; 2016 Mar; 13(3):329-33. PubMed ID: 26784741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of (S)-N'-nitrosonornicotine in U.S. tobacco products.
    Stepanov I; Yershova K; Carmella S; Upadhyaya P; Hecht SS
    Nicotine Tob Res; 2013 Jul; 15(7):1305-10. PubMed ID: 23212437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine addiction among American youth.
    Grabiak BR
    ORL Head Neck Nurs; 1996; 14(2):13-5. PubMed ID: 8788361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco.
    Kessler DA; Barnett PS; Witt A; Zeller MR; Mande JR; Schultz WB
    JAMA; 1997 Feb; 277(5):405-9. PubMed ID: 9010173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of TSNA in U.S. Tobacco and Moist Smokeless Tobacco Products.
    Oldham MJ; Lion KE; Phillips DJ; Morton MJ; Lusso MF; Harris EA; Jordan JL; Franke JE; Strickland JA
    Toxicol Rep; 2020; 7():752-758. PubMed ID: 32612935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Public Health Standard in Action-Analysis of the US Food and Drug Administration's IQOS Review.
    Berman ML; Glasser AM
    JAMA Oncol; 2020 Dec; 6(12):1864-1865. PubMed ID: 32822466
    [No Abstract]   [Full Text] [Related]  

  • 15. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India.
    Stepanov I; Hecht SS; Ramakrishnan S; Gupta PC
    Int J Cancer; 2005 Aug; 116(1):16-9. PubMed ID: 15756678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA's proposed regulation of the sale and promotion of tobacco products to minors.
    Zieve AM
    Public Health Rep; 1996; 111(3):280-5. PubMed ID: 8643823
    [No Abstract]   [Full Text] [Related]  

  • 17. Amendments to general regulations of the Food and Drug Administration. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Nov; 75(229):73951-5. PubMed ID: 21121182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users.
    Stepanov I; Hecht SS
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):885-91. PubMed ID: 15824160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further amendments to general regulations of the Food and Drug Administration to incorporate tobacco products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(22):5171-6. PubMed ID: 22359802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's failure to address the lack of generalisability of antidepressant efficacy trials in product labelling.
    Zimmerman M
    Br J Psychiatry; 2016 Jun; 208(6):512-4. PubMed ID: 27251690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.